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S U M M A R Y
Objectives: Hepatitis B virus (HBV) and human immunodeﬁciency virus (HIV) share common routes of
blood-borne transmission. In HBV mono-infected Sudanese individuals, genotypes D, E, and A circulate.
The objective of this study was to molecularly characterize HBV from HBV/HIV co-infected individuals.
Methods: The polymerase overlapping the S region and the basic core promoter (BCP/PC) of HBV from
32 hepatitis B surface antigen (HBsAg)-positive and 18 HBsAg-negative serum samples were ampliﬁed
and sequenced.
Results: HBV from 37 samples was successfully genotyped and the genotype distribution was 46.0% D,
21.6% E, 18.9% A, and 13.5% D/E recombinant. Compared to mono-infected individuals, the frequencies of
the D/E recombinant and genotype A were higher in HBV/HIV co-infected patients, as was the intra-
group divergence of genotype E. BCP/PC mutations affecting hepatitis B e antigen (HBeAg) expression at
the transcriptional and translational levels were detected. Two HBsAg-positive individuals had pre-S
deletion mutants. The following mutations in the S region could account for the HBsAg negativity:
sM133T, sE164G, sV168G, and sS174N. No primary drug resistance mutations were found.
Conclusions: In HBV/HIV co-infected Sudanese patients, the ratio of genotype A to non-A was higher than
that in mono-infected patients. The genotype E intra-group divergence in HBV/HIV co-infected
individuals was signiﬁcantly higher than that in HBV mono-infected patients.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Hepatitis B virus (HBV), the smallest DNA virus that infects
humans, is a member of the Hepadnaviridae family and it causes
acute and chronic liver disease. Human immunodeﬁciency virus
(HIV) is an enveloped RNA virus that replicates by reverse
transcription.1 HBV and HIV share common routes of blood-borne
transmission, but they differ in efﬁciency of transmission and in
their geographic distribution.2 Worldwide, it has been estimated
that 10% of the 34 million people infected with HIV have chronic
HBV infection.2* Corresponding author. Tel.: +27(0) 11 488 3100; fax: +27(0) 86 529 6806.
E-mail address: Anna.Kramvis@wits.ac.za (A. Kramvis).
http://dx.doi.org/10.1016/j.ijid.2014.07.002
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).In Sudan, the prevalence of HBV infection ranges from 3.9% in
blood donors in Khartoum3 to 26% in patients seen in outpatient
clinics in Juba in southern Sudan.4 The prevalence of HIV in adults
in Sudan was estimated to be 1.4% in 2008,5 and according to the
Sudan National AIDS Control Programme (SNAP), this ﬁgure had
decreased to 0.52% in 2011.6 It is very difﬁcult to surmise the true
prevalence of HBV/HIV co-infection in Sudan from the data
available because of the paucity of data and the wide time span
between studies.
Two studies, carried out 24 years ago, determined the
prevalence of HBV/HIV co-infection in Sudan, using serological
techniques. The ﬁrst study showed 14% HBV infection among HIV-
negative individuals who were sexually active heterosexuals in the
northeast of Sudan.7 The second study, among soldiers in eastern
Sudan, showed 1.7% HIV infection and 25% hepatitis B surface
antigen (HBsAg) positivity, with only 0.8% being co-infected withciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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225 of 358 (62.8%) HIV-infected individuals from Khartoum to
have at least one HBV serological marker, with 129 (36%) being
HBV DNA-negative and 96 (26.8%) being HBV DNA-positive by
real-time PCR (RT-PCR).9 HBV DNA was detected together with
HBsAg in 42 (11.7%) and without HBsAg in 54 (15.1%) of the
participants.9 Of these, 35 (9.8%) had a viral load <200 IU/ml (<2.3
log10 IU/ml) and therefore true occult hepatitis B infection (OBI),
10
and 19 (5.3%) had viral loads >200 IU/ml (>2.3 log10 IU/ml) and
were therefore HBsAg-covert.11
As a result of the lack of proofreading activity of the viral
polymerase, HBV displays considerable sequence heterogeneity,
leading to its classiﬁcation into at least nine genotypes.12–20 These
are deﬁned by inter-genotypic differences of more than 7.5% in the
complete HBV genome.12,21,22 It is considered that genotypes play
an important role in treatment management and disease progno-
sis.23–25 In Sudan, close to 60% of liver disease patients were found
to be infected with genotype D (predominantly subgenotype D1),
30% with genotype E, 8.5% with genotype A, and 2.5% with D/E
recombinant.26 In contrast, in Sudanese blood donors, genotype E
was found to predominate (55%), followed by genotype D (39%), D/
E recombinant (4%), and genotype A (2%).3
No information exists regarding the distribution of HBV
genotypes in HIV-infected individuals in Sudan. The objectives
of this study were to genotype and molecularly characterize HBV
and to determine possible virological characteristics that could
differentiate isolates from HBsAg-positive and HBsAg- negative
HIV-infected Sudanese patients.
2. Patients and methods
2.1. Ethical considerations
This study was a continuation of a previous study on HBV/HIV
co-infection among adult Sudanese HIV patients.9 The study was
originally approved by the Ethics Committee of the Faculty of
Medicine, University of Khartoum and the National Ethics
Committee at the Federal Ministry of Health. All patients provided
signed informed consent, and the clinical report forms were
completed by qualiﬁed practitioners. The study was approved by
the Human Research Ethics Committee of the University of the
Witwatersrand.
2.2. Serum samples
Serum samples were collected from 358 HIV-positive treat-
ment-naı¨ve patients and 96 were positive for HBV DNA using RT-
PCR.9 Fifty of these 96 were selected randomly for downstream
genotyping and molecular analysis of the HBV.
2.3. DNA extraction
DNA was extracted from 200 ml of serum using the QIAamp
DNA Blood Mini Kit (Qiagen GmbH, Germany), in accordance with
the manufacturer’s instructions, and eluted in 100 ml of elution
buffer.
2.4. PCR
Two regions of the HBV genome were ampliﬁed. The basic core
promoter/precore (BCP/PC) region (1742–1900 from EcoR1) was
ampliﬁed using a minor modiﬁcation of the method described by
Takahashi et al.;27 primers 1606(+) (1606–1625 from the EcoR1
site) and 1974() (1974–1955 from the EcoR1 site) were used for
the ﬁrst round and 1653(+) (1653–1672 from the EcoR1 site) and
1959() (1959–1940 from the EcoR1 site) for the second round.Region 2624–1240 from EcoR1, covering part of the polymerase
region and overlapping the complete S region (2848–835 from the
EcoR1 site) (P/S) was ampliﬁed using primers 2410(+) (2410–2439
from the EcoR1 site) and 1314() (1314–1291 from the EcoR1 site)
for the ﬁrst round and 2451(+) (2451–2482 from EcoR1site) and
1280() (1280–1254 from EcoR1 site) for the second round.28
2.5. Sequencing
The BigDye Terminator v3.0 Cycle Sequencing Ready Reaction
Kit (Applied Biosystems, Foster City, CA, USA) was used and
sequencing was performed with an ABI 3130XL Genetic Analyzer
(Applied Biosystems). The three overlapping fragments of the
region 2624–1240 from EcoR1 obtained were assembled using the
Fragment Merger tool.29 Sequences were deposited in GenBank
under accession numbers KM108588–KM108626.
2.6. Phylogenetic analysis
A neighbour-joining phylogenetic tree with a bootstrap of
1000 replicates was constructed using MEGA 530 or PHYLIP
(Phylogeny Inference Package, version 3.69). DNADIST consecu-
tively with NEIGHBOR (neighbour-joining) were used to generate
dendrograms, which were viewed in TreeView.31,32
3. Results
3.1. HBV serology, ampliﬁcation, and quantiﬁcation of HBV DNA
Of the 50 HBV DNA-positive patients selected randomly, 28 were
males. The mean patient age  standard deviation (SD) was
35  8.1 years. The median alanine aminotransferase (ALT) level was
6.15 (interquartile range (IQR) 3.3–11.8) IU/l (reference range 5–40 IU/
l)33 and the median HBV DNA viral load was 4.2 (IQR 3.56–6.67) log IU/
ml. Thirty-two (64%) were HBsAg-positive and 18 (36%) were HBsAg-
negative. Only six were hepatitis B e antigen (HBeAg)-positive. No
difference in age, gender, HBsAg prevalence, or ALT levels was observed
between the 50 samples (selected randomly for further analyses) and
the original 96 HBV DNA-positive samples.9 Of the 18 HBsAg-negative
patients, 10 had viral loads <200 IU/ml (<2.3 log10 IU/ml), and thus
according to the Taormina deﬁnition, were true OBI.10 The remaining
eight had viral loads >200 IU/ml (>2.3 log10 IU/ml) and therefore were
HBsAg-covert11 (Table 1). No difference in age, gender, or ALT levels
was observed between the true OBI and HBsAg-covert cases.
3.2. HBV genotyping and phylogenetic analysis
Sequences were obtained for 46 of the 50 samples: 27 samples
in both the BCP/PC and the P/S region, 12 in the BCP/PC alone, and
seven in the P/S region only. For three samples, however, the
sequences of the S region were not of good quality and therefore
could not be used for genotyping.
In total, 37 HBV isolates were successfully genotyped using one
of the two methods; 31 of 37 were genotyped using phylogenetic
analysis of the P/S region (Figure 1).
The BCP/PC region sequences could be used to differentiate
between genotype A and non-A. Six out of 37 had 1858C
characteristic of genotype A and all belonged to subgenotype A1
because they had 1809–1812 TCAT and 1888A. Six samples had
1858T characteristic of non-A genotypes, but this region cannot
differentiate between genotype D and E and thus these samples
could not be genotyped.
The genotype distribution of the 37 isolates was as follows: 17
(46.0%) genotype D, eight (21.6%) genotype E, seven (18.9%)
genotype A, and ﬁve (13.5%) putative D/E recombinant. If we
include the 13 (26%) samples that could not be genotyped, the
Table 1
Characteristics of HBV isolated from HIV-positive individuals
HBsAg status Isolate Patient characteristics Virus characteristics HBV infection
Gender Age, years ALT IU/l Genotype Subgenotype Viral load IU/ml log
Positive SDH001 Male 50 24 D D1 6.82 Overt
SDH020 Female 26 19.9 E NA 4.25 Overt
SDH025 Female 23 7.6 D D2 6.86 Overt
SDH028 Male 31 10.6 - - 4.74 Overt
SDH043 Female 34 4.6 - - 3.46 Overt
SDH049 Male 45 11.8 D D1 5.65 Overt
SDH050 Male 48 0.4 D D1 9.16 Overt
SDH052 Male 38 16.1 D D6 7.28 Overt
SDH065 Male 32 18.2 D D1 8.19 Overt
SDH071 Male 35 1.2 D/E NA 4.56 Overt
SDH075 Female 32 5.5 D D1 3.73 Overt
SDH078 Male 25 7.6 - - 4.08 Overt
SDH079 Male 25 11.7 - - 3.34 Overt
SDH084 Male 25 8.9 E NA 6.23 Overt
SDH097 Female 23 6.4 D/E NA 4.53 Overt
SDH111 Female 36 7.6 - - 3.67 Overt
SDH113 Female 42 27.5 D/E NA 3.37 Overt
SDH116 Male 23 5.5 E NA 4.19 Overt
SDH120 Male 27 17.8 E NA 7.83 Overt
Positive SDH122 Female 38 8.4 - - 4.00 Overt
SDH123 Female 35 15.2 D D1 7.20 Overt
SDH146 Female 33 8 - - 4.17 Overt
SDH153 Female 28 5.9 D D1 4.16 Overt
SDH184 Female 30 5.9 A A1 7.00 Overt
SDH188 Male 28 4.2 E NA 4.95 Overt
SDH189 Female 30 0.8 - - 3.42 Overt
SDH193 Male 45 5.9 E - 8.16 Overt
SDH194 Female 37 0.8 D D6 3.14 Overt
SDH195 Male 38 3.3 A A1 3.59 Overt
SDH196 Male 38 13.1 - - 3.13 Overt
SDH199 Female 35 3.8 A A1 3.08 Overt
SDH200 Male 45 5.6 A A1 7.12 Overt
Negative SDH005 Female 45 12.3 D D1 <2.3 OBI
SDH007 Female 30 14 D D2 3.55 HBsAg-covert
SDH022 Male 27 7.2 D D1 <2.3 OBI
SDH036 Female 30 5.9 - - <2.3 OBI
SDH042 Male 41 0.8 D D1 <2.3 OBI
SDH058 Male 42 8.4 D D6 2.33 HBsAg-covert
SDH061 Male 50 1.4 D D6 <2.3 OBI
SDH087 Male 22 11.8 D D2 <2.3 OBI
SDH119 Female 35 11.8 D/E NA <2.3 OBI
SDH126 Male 45 2.9 A A1 <2.3 OBI
Negative SDH130 Male 37 2.2 - - 3.92 HBsAg-covert
SDH147 Female 23 4.6 - - 5.45 HBsAg-covert
SDH152 Female 38 2.1 E NA 4.62 HBsAg-covert
SDH160 Male 37 1.2 - - 4.01 HBsAg-covert
SDH172 Female 35 3.8 A A1 <2.3 OBI
SDH174 Male 40 3.3 E NA 4.38 HBsAg-covert
SDH192 Male 54 7.9 D/E NA 2.78 HBsAg-covert
SDH197 Male 40 2.5 A A1 <2.3 OBI
(-), no genotype assignment; NA, not applicable; Overt, HBsAg-positive; OBI, occult hepatitis B infection, HBsAg-negative with viral loads <200 IU/ml (<2.3 log10 IU/ml);
HBsAg-covert, HBsAg-negative with viral loads >200 IU/ml (>2.3 log10 IU/ml).
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genotype D, 16% (8/50) with genotype E, 14% (7/50) with genotype
A, and 10% (5/50) were infected with a putative D/E recombinant.
The genotype distribution did not differ between HBsAg-positive
and HBsAg-negative sera, or between HBsAg-covert and OBI
patients. Comparing the genotype distribution of HBV isolates in
the Sudanese HBV/HIV co-infected individuals to mono-infected
liver disease patients,26 the frequencies of genotype A and the D/E
recombinant were higher in HIV co-infected patients (P < 0.05)
(Figure 2).
The HBV genotypes were further classiﬁed into subgenotypes
using the following criteria: phylogenetic analysis of the P/S region,
inter-group divergence, signature amino acids, and geographical
distribution.20 Ten of 17 genotype D isolates belonged to sub-
genotype D1 (58.8%), two to D2 (11.7%), and ﬁve to D6 (29.5%); the
one genotype A isolate belonged to subgenotype A1 (Figure 1).
SDH042-OBI was an outlier of the cluster containing subgenotypesof D1–D3 and D5. However, when the analysis was repeated using
only the complete S region (2848–835 from the EcoR1 site), SDH042-
OBI clustered with subgenotype D1 (Figure 1A).
3.3. Genetic diversity of Sudanese strains
The intra-group divergence of the HBV isolated from the HBV/
HIV co-infected individuals in the present study was compared to
isolates from HBV mono-infected liver disease patients26
(Figure 3). The intra-group divergence of genotype E from HBV
mono-infected liver disease patients was lower than the intra-
group divergence of genotype D from HBV mono-infected liver
disease patients (p < 0.05), whereas in HBV/HIV co-infected
individuals this difference was not observed (Figure 3). Moreover,
only the intra-group divergence of genotype E from HBV/HIV
co-infected individuals was higher than the intra-group diver-
gence of genotype E from HBV mono-infected liver disease patients
Figure 1. A rooted phylogenetic tree of 31 HBV isolates from HBV/HIV co-infected individuals; the region 2624–1240 from EcoR1, covering the polymerase region and overlapping
complete S (2848–835 from the EcoR1 site). The 30 isolates sequenced in the present study have the preﬁx SDH and are shown in bold, followed by the clinical status (HBsAg-
positive, HBsAg-covert, and occult hepatitis B infection (OBI)). These were compared using neighbour-joining with 30 HBV sequences from Sudanese liver disease patients26
shown in italics and 55 reference sequences, labelled with their accession numbers and country of origin. Bootstrap statistical analysis was performed using 1000 datasets and the
percentages are indicated on the nodes. Box A illustrates the clustering of SDH042-OBI relative to the subgenotypes of D when only the complete S (2848–835 from the EcoR1 site)
was analyzed. The different subgenotypes are represented by different shapes: subgenotype D1 (squares), D2 (triangles), D3 (inverted triangles), and D5 (circles).
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Figure 2. Ratio of the distribution of HBV genotypes in mono-infected liver disease patients26 compared to HBV/HIV co-infected individuals.
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co-infected individuals was 83% higher than from HBV mono-
infected liver disease patients, whereas it was only 3.7% higher for
genotype D.
3.4. Analysis of the BCP/PC region
BCP/PC mutations can down-regulate or abolish the expression
of HBeAg at the transcriptional, translational, or post-translational
levels.34 Of the six isolates from HBeAg-positive sera, two had
mutations at the BCP: SDH052 (HBsAg-positive, genotype D) had
A1762G, and SDH084 (HBsAg-positive, genotype E) had A1762T/
G1764A. The remaining four isolates, from HBeAg-positive
patients, had wild-type BCP/PC. Thirty of the 44 isolates from
HBeAg-negative individuals (17 HBsAg-positive and 13 HBsAg-
negative) were successfully ampliﬁed and sequenced in the BCP/PC
region. Twenty-ﬁve isolates had genotype assignments:
11 belonged to genotype D, ﬁve to genotype E, six to genotype
A, and three were D/E recombinants. The mutations found in the
isolates from HBeAg-negative patients are shown in Table 2. Three
isolates had A1762T alone and three isolates had start codon
mutations at 1814–1816. Ten of the 26 isolates had G1896A. EvenFigure 3. Comparison of the genetic diversity of genotype D and E isolated from HBV
mono-infected liver disease patients and from HBV/HIV co-infected individuals.though 1858T is found in both genotypes D and E and allows for
G1896A to occur, G1896A was found more frequently in genotype
E and the D/E recombinant compared to genotype D (p < 0.05).
Moreover, G1896A occurred more frequently in isolates from
HBsAg-positive compared to HBsAg-negative individuals
(p < 0.05). G1896A occurred together with A1762T/G1764A in
two genotype E isolates. The mutation C1766T was found in ﬁve
genotype A isolates only (p < 0.05).
3.5. Analysis of the pre-S1, pre-S2, surface, and polymerase regions
The sequence of the P/S region (2624–1240 from the EcoR1
site) was obtained for 31 HBV isolates from HBV/HIV co-infected
individuals. Of the 31 isolates, 20 were from HBsAg-positive and
11 from HBsAg-negative patients. Pre-S deletions were found in
two genotype E isolates. SDH084 HBsAg-positive had a 93-
nucleotide deletion in the pre-S1 and pre-S2 regions, from 3178 to
58 from the EcoR1 site, which led to an 8 amino acid deletion from
position 111 to 118 in the pre-S1 and 23-amino acid deletion from
position 1 to 23 in the pre-S2. SDH120 HBsAg-positive had a 36-
nucleotide deletion in the pre-S2 starting from nucleotide 5 to
40 from the EcoR1 site, which resulted in a 12-amino acid deletion
from position 6 to 17. Table 3 shows the various mutations in the
polymerase and overlapping S regions.
4. Discussion
In our recently completed study on 358 HIV-positive partici-
pants, 225 (62.8%) had serological evidence of past or current HBV
infection. HBV DNA was detected in 96 (26.8%): 42 (11.7%) with an
overt HBsAg-positive infection and 54 (15.1%) who were HBsAg-
negative with hepatitis B core antibodies (anti-HBc) as a marker of
past HBV infection.9 Fifty of the 96 HBV DNA-positive samples
were randomly selected for molecular characterization of the HBV.
The distribution ratio of HBV genotypes D and E found in HBV/
HIV co-infected individuals (Figure 2), did not differ from that
found in HBV mono-infected liver disease patients and there was
no difference in their clustering in the phylogenetic tree
(Figure 1).26 However, genotype A and the putative D/E recombi-
nant were found at a higher frequency in HBV/HIV co-infected
individuals compared to HBV mono-infected liver disease patients
(genotype A, 18.4% vs. 8.6%; D/E, 13.2% vs. 2.5%; p < 0.05).
Table 2
Molecular characteristics of the BCP/PC region of HBV isolated from HBeAg-negative HIV co-infected individuals
HBsAg Isolate Genotype Subgenotype Viral load
IU/ml log
1753 1762–1764 1766 1768 1809–1812 1814–1816 1817 1850 1858 1862 1888 1896 1899
Positive SDH025 D D2 6.86 T AG C T GCAC ATG C T T G G A G
SDH049 D D1 5.65 T AG C T GCAC ATT C T T G G G A
SDH065 D D1 8.19 T AG G T GCAC ATG C T T G G A G
SDH071 D/E NA 4.56 T AG C T GCAC ATG C T T G G A G
SDH075 D D1 3.73 T AG C T GCAC ATG C T T G G G C
SDH097 D/E NA 4.53 T AG C T GCAC ATG C T T G G A A
SDH116 E NA 4.19 T AG C T GCAC ATG C T T G G A A
SDH120 E NA 7.83 T AG G T GCAC ATG C T T G G A G
SDH123 D D1 7.2 G TG T A GCAC ATG C T T G G G G
SDH153 D D1 4.16 T AG C T GCAC ATG C T T G G A G
SDH188 E NA 4.95 T TA C T GCAC ATG C T T G G A G
SDH194 D D6 3.14 G AG C T GCAC ATG C T T G G G G
SDH195 A A1 3.59 T AG T T TCAT ATG C A C G A G G
SDH199 A A1 3.08 T AG C T TCAT ATG C A C G A G G
SDH200 A A1 7.12 T GT T T TCAT ATG C A C G A G G
Negative SDH007 D D2 3.55 T AG C T GCAC AAG C T T G G G G
SDH042 D D1 <2.3 T AG C T GCAC ATG C T T G G G G
SDH058 D D6 2.33 G TG C T GCAC ATG C T T G G G G
SDH061 D D6 <2.3 G TG C T GCAC ATG C T T G G G G
SDH126 A A1 <2.3 T AG T T TCAT ATG C A C G A G G
Negative SDH152 E NA 4.62 T AG C T GCAC ATT C T T G G G G
SDH172 A A1 <2.3 T AG T T TCAT ATG C A C T A G G
SDH174 E NA 4.38 T AG C T GCAC ATG C T T G G G G
SDH192 D/E NA 2.78 T AG C T GCAC ATG C T T G G A A
SDH197 A A1 <2.3 T AG T T TCAT ATG C A C G A G G
BCP/PC, basic core promoter/precore; HBV, hepatitis B virus; HBeAg, hepatitis B virus e antigen; NA, not applicable.
Table 3
S and polymerase mutations found in HBV isolated from HBV/HIV co-infected individuals
Type of mutation HBV region Mutation Genotype HBsAg status
Vaccine and immune escape Pre-S1 I48E A Positive
Pre-S2 Q10R D/E Positive
R48T E Positive
D Positive
D Positive
D Negative
PreS2F22 mutation Pre-S2 F22S E Positive
D Positive
F22L D/E Positive
E Positive
E Positive
D/E Positive
a0 determinant mutation S P120T E Positive
M133T D Negative
G145R E Positive
E164G D/E Negative
E Negative
HBV ‘reactivation’ marker S V168G E Positive
A Positive
D/E Negative
HBV ‘reactivation’ marker S S174Na D Negative
D/E Negative
D/E Negative
Overlapping polymerase drug resistance mutations RT/POL A181 D/E Negative
Q215S D Positive
D Positive
I233 E Positive
HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen; S, S region; RT/POL, reverse transcriptase/polymerase; NA, not applicable.
a Signiﬁcant association.
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blood donors, with genotype E predominating.3
With regard to the subgenotype distribution, in agreement with
previous studies of HBV in Sudan,3,26 subgenotype D1 was found to
predominate in the HBV/HIV co-infected individuals (Figure 1).
Thus the predominant subgenotype of D found in Sudan is D1. This
is the subgenotype of D that prevails in the Mediterranean region,
Arabian subcontinent, and in China.30 Subgenotype A1 was found
circulating in HBV/HIV co-infected individuals and liver diseasepatients,26 whereas subgenotype A2 was found in blood donors.3
Subgenotype A1 predominates in eastern and southern Africa and
subgenotype A2 is the subgenotype of A predominating outside
Africa.35
Following the calculation of the intra-group divergence of
genotype D and E isolates from HBV mono-infected liver disease
patients and HBV/HIV co-infected individuals, it was found that
genotype E from HBV mono-infected liver disease patients had a
low diversity of 1.8% compared to 2.7% for genotype D from HBV
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type E has been characterized to have a low diversity compared to
other genotypes and subgenotypes of HBV. Using more than
400 sequences of HBV isolated from West African countries, the
genetic diversity of genotype E was found to be 0.73% for the S gene
and 1.7% for the complete genome.36 Complete genomes of
genotype E isolates from Namibia, Angola, and Madagascar were
found to differ from each other by only 1.2%.37 Genotype D has
been shown to be the most divergent genotype after genotype C.38
The signiﬁcant difference in intra-group divergence of genotypes D
and E seen in mono-infected individuals, however, was not seen in
HBV/HIV co-infected individuals, and the intra-group divergence
of genotype E in HBV/HIV co-infected individuals was signiﬁcantly
higher than that in HBV mono-infected liver disease patients
(Figure 3). It appears that in HBV mono-infected liver disease
patients, who are immune competent, the genetic diversity of
genotype E is constrained, whereas in HBV/HIV co-infected
individuals there is an expansion of the quasi-species. HIV
infection and its associated immune suppression might alter the
heterogeneity of the virus and increase the genetic variability of
HBV,39 which may be as a result of the reactivation of occult HBV
that can survive in the presence of immune selection.
The 81% prevalence of HBeAg negativity in HBV/HIV co-infected
patients9 was lower than in HIV-negative patients, where 88%
were HBeAg-negative.26 When comparing the mutation distribu-
tion in BCP/PC at 10 loci that can affect HBeAg expression (1762,
1764, 1809–1812, 1814–1816, and 1896), we found that mutations
at 1762 and 1764 occurred less frequently in isolates from HBV/
HIV co-infected individuals compared to those from mono-
infected liver disease patients (p < 0.05). Mutations at 1762 and
1764 can reduce the transcription of precore mRNA, resulting in
lower expression of HBeAg.40
Two genotype E HBV isolates from HBsAg-positive HBV/HIV co-
infected individuals had deletions in the pre-S1 and pre-S2 regions.
No deletions were detected in genotype D isolates. The 12 amino
acid deletion mutant was found in the pre-S2, whereas the
31 amino acid deletion covered the 30 pre-S1 and 50 pre-S2. Similar
deletion mutants were found in genotype D and E isolates from
Sudanese HBV mono-infected liver disease patients,26 but only in
genotype E isolates from blood donors in Sudan3 and Guinea.41 The
deletion mutants in HBV genotype E isolates from HBV mono-
infected liver disease patients were mainly in hepatocellular
carcinoma (HCC) patients, whereas this was not the case for
genotype D isolates.26 Deletion mutants in the pre-S have been
implicated in the progression of liver diseases in genotypes B and
C42 and the development of HCC in genotype A.43 The presence of
deletion mutants in HBV from HBV/HIV co-infected individuals has
been described in genotype A, both subgenotype A144 and
subgenotype A2.45 PreS2F22L was found in four isolates from
HBsAg-positive HBV/HIV co-infected individuals and was found to
be signiﬁcantly associated with G1896A. PreS2F22L has been
signiﬁcantly associated with cirrhosis46 and has been shown to be
a risk factor for the development of HCC in Chinese patients
infected with genotype C47 and in Indian patients infected with
genotype D.46,48 HIV infection has been intimated to increase the
hepatocarcinogenic potential of HBV.49
In agreement with other studies in HIV-infected individuals,
HBsAg negativity was frequent.44,50 The HBsAg negativity resulted
in both OBI (viral loads <200 IU/ml (<2.3 log10 IU/ml))
10 and
HBsAg-covert infection (viral loads >200 IU/ml (>2.3 log10 IU/
ml)).11 In the case of OBI, the inability to detect HBsAg could be as a
result of its presence at very low concentrations, below the
detection limits of the assay. In the case of the HBsAg-covert
infection, the HBsAg negativity may be the result of the presence of
detection escape mutations in the ‘a’ determinant. Although we
found no mutational pattern that could differentiate the HBVisolated from HBsAg-negative individuals from those isolated from
HBsAg-positive ones, there were a number of mutations that could
account for the HBsAg negativity (Table 3). These mutations
include ps2R48T, sM133T, sE164G, sV168G, and sS174N and have
also been found in strains circulating in HBsAg-negative HIV-
infected individuals infected with subgenotype A1 of HBV.44 Of
particular interest is S174N, which has only been detected in HBV
from HBsAg-negative HBV/HIV co-infected individuals44,51 and has
been described as a reactivation marker in a single patient infected
with subgenotype A2.51 No primary drug resistance mutations
were detected in the present study. This is not unexpected because
all patients recruited in this study were treatment-naı¨ve.
The distributions of genotypes D and E of HBV found in HBV/HIV
co-infected individuals did not differ from those found in HBV
mono-infected liver disease patients. However, the ratio of
genotype A to non-A in HIV co-infected individuals was found
to be higher than that in mono-infected patients. A predominance
of genotype A of HBV in HIV co-infected individuals has also been
reported by others.44,45,52 Subgenotype A1 is the predominant
strain circulating in countries neighbouring Sudan, including
Kenya53 and Uganda.54 In a previous study, it was shown that the
only factor that differentiated HBV-positive HIV-infected individ-
uals from those who were HBV-negative was the number of
lifetime sexual contacts,11 thus implicating sexual transmission of
this subgenotype.44 Furthermore, the intra-group divergence of
genotype E in HBV/HIV co-infected individuals was signiﬁcantly
higher than that in HBV mono-infected patients. We detected pre-S
deletions, mutations associated with severe liver disease, detec-
tion-escape mutations, as well as reactivation markers, in the HBV
isolated from HIV co-infected individuals. These alterations can
have important implications in exacerbating the clinical manifes-
tations of HBV infection, its detection, and clinical management.
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